CompletedNot Applicable

Prognosis Related to Induced Thrombopenia With Heparin Under Venoarterial ECMO in Reanimation

39 participantsStarted 2016-01-01

Plain-language summary

Thrombocytopenia is a frequent and serious adverse event in patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock. Similarly to postcardiac surgery patients, heparin-induced thrombocytopenia (HIT) could represent the causative underlying mechanism. However, the epidemiology as well as related mortality regarding HIT and VA-ECMO remains largely unknown. The investigators aimed to define the prevalence and associated 90-day mortality of HIT diagnosed under VA-ECMO.This retrospective study included patients under VA-ECMO from 20 French centers between 2012 and 2016.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Patient hospitalized in intensive care for a cardiovascular failure requiring the setting up of an ECMO-VA * ECMO-VA duration ≥ 3 days * HIT confirmed by immunological tests * Patient affiliated to a Social Security scheme Exclusion Criteria: * Known antecedent of TIH prior to cannulation * Pregnant woman * ECMO-VA following cardiopulmonary arrest or septic shock

What they're measuring

Death

Timeframe: 90 days after inclusion

Trial details

NCT IDNCT03979625

SponsorCentral Hospital, Nancy, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-04-30

View on ClinicalTrials.gov More Heparin-induced Thrombocytopenia trials